SubHero Banner

Pluvicto(lutetium Lu 177 vipivotide tetraxetan) – New drug approval

March 23, 2022 - Novartis announced the FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan), for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Download PDF